Thursday, 12 November 2026European Markets

Goldman Sachs exits consumer banking after $4B in losses, refocuses on institutional finance

Goldman Sachs has sold its Marcus loan portfolio, GreenSky platform, and Personal Financial Management unit while offloading the Apple Card program to JPMorgan by 2026. The Wall Street bank absorbed roughly $4 billion in consumer banking losses before pivoting to institutional finance through its new Capital Solutions Group and acquisitions of Industry Ventures and Innovator Capital Management in 2025.

Goldman Sachs exits consumer banking after $4B in losses, refocuses on institutional finance
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Goldman Sachs has completed its retreat from consumer banking after accumulating approximately $4 billion in losses, selling Marcus loans in 2023, the GreenSky platform in 2024, and transferring the Apple Card program to JPMorgan in 2026. Creative Planning acquired Goldman's Personal Financial Management unit in 2023.

The exit contrasts sharply with Goldman's 2016 consumer banking launch. Mortgage loan origination costs at Fannie Mae and Freddie Mac average $13,000 per loan, illustrating the cost burden traditional banks face in retail operations. Specialized fintech firms and digital-native lenders operate with lower overhead structures.

Goldman formed its Capital Solutions Group in 2025 and acquired Industry Ventures and Innovator Capital Management the same year. The bank is consolidating around institutional clients, investment banking, and asset management—businesses where relationship complexity and deal size favor traditional investment banks over automated platforms.

European universal banks face similar pressure. Deutsche Bank, BNP Paribas, and UBS maintain both retail and institutional operations, but AI-driven cost advantages increasingly favor specialized players. Digital banks like N26 and Revolut handle routine retail transactions at lower cost per customer than traditional branches.

Goldman's strategic shift raises questions about European banking structure. Universal banking models rely on cross-subsidization between retail deposits and investment banking operations. If retail banking becomes structurally unprofitable for institutions lacking scale or digital efficiency, European banks may need to choose specialization.

EU banking competition could intensify as U.S. investment banks concentrate on institutional clients in Europe while fintech companies capture retail segments. Goldman's European operations focus on corporate advisory, capital markets, and wealth management for high-net-worth clients—areas less vulnerable to AI disruption than mass-market lending.

The pattern suggests a bifurcation: specialized fintech for standardized retail services versus relationship-driven banks for complex institutional finance. European regulators face challenges maintaining competitive retail banking markets if economies of scale and AI automation create winner-take-all dynamics favoring either massive digital platforms or niche institutional players.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com